Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Bernard GR, et al. Among authors: laterre pf. N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001. N Engl J Med. 2001. PMID: 11236773 Free article. Clinical Trial.
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators. Angus DC, et al. Among authors: laterre pf. Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.
Anticoagulant therapy in acute lung injury.
Laterre PF, Wittebole X, Dhainaut JF. Laterre PF, et al. Crit Care Med. 2003 Apr;31(4 Suppl):S329-36. doi: 10.1097/01.CCM.0000057912.71499.A5. Crit Care Med. 2003. PMID: 12682461 Review.
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Dhainaut JF, et al. Among authors: laterre pf. Intensive Care Med. 2003 Jun;29(6):894-903. doi: 10.1007/s00134-003-1731-1. Epub 2003 Apr 24. Intensive Care Med. 2003. PMID: 12712239 Clinical Trial.
320 results